wire - news in brief

« BACK

Health



Results 1 - 50 of 1691.
1 2 3 4 5 ... 34 Next »


Pharmacology - Health - 22.05.2019
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c

Health - Pharmacology - 21.05.2019
Bern Center for Precision Medicine inaugurated
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.

Pharmacology - Health - 16.05.2019
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO   Primary results of

Health - 16.05.2019
Flu Prevention in Switzerland
Flu Prevention in Switzerland
A nationwide systematic survey of 97 organisations carried out by Swiss TPH shows that authorities, hospitals, institutions and organisations in Switzerland have long been committed to efforts against the flu.

Health - Pharmacology - 16.05.2019
Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina

Pharmacology - Health - 16.05.2019
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off

Health - Pharmacology - 14.05.2019
New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.

Health - 14.05.2019
Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc
Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review Roche and Spark Therapeutics, Inc.

Pharmacology - Health - 10.05.2019
Novartis data at AAN show Gilenya is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya  (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions   There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil

Pharmacology - Health - 10.05.2019
Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio

Pharmacology - Health - 08.05.2019
Novartis data at AAN show Mayzent’s positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients   Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS   EXPAND findings demonstrate that SPMS patients treated earlier in the cou

Health - Pharmacology - 07.05.2019
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively   Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity   These fin

Health - Life Sciences - 07.05.2019
Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting
In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New data from the dose-finding Part 1 of SUNFISH reinforce risdiplam as a promising investigational therapy for people with Type 2 or 3 spinal muscular atrophy No treatment-related safety findings leading to withdrawal seen to date in risdiplam trials Roche today announ

Pharmacology - Health - 06.05.2019
FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The

Pharmacology - Health - 02.05.2019
Novartis to highlight extensive long-term safety and efficacy data of Aimovig across the spectrum of migraine at AAN
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average   Separate study showed

Innovation / Technology - Health - 02.05.2019
Moving people and technology
On 2 and 3 May 2020 ' exactly one year from now ' the Swiss Arena will open its doors for the next edition of the Cybathlon.

Health - Business / Economics - 24.04.2019
Two Decades of Swiss Leadership for New Malaria Medicines
Two Decades of Swiss Leadership for New Malaria Medicines
On World Malaria Day 2019, Swiss organizations look back on a long history of successful public-private collaboration for new malaria medicines.

Health - Pharmacology - 23.04.2019
Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.

Pharmacology - Health - 15.04.2019
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries   Filing is based on Phase III data from the HAWK and HARRIER

Pharmacology - Health - 15.04.2019
Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.

Health - Innovation / Technology - 12.04.2019

Health - Pharmacology - 09.04.2019
Animal-assisted therapy improves social behavior in patients with brain injuries
Animal-assisted therapy improves social behavior in patients with brain injuries
Animal-assisted therapy can foster social competence in patients with brain injuries and increase their emotional involvement during therapy. These were the findings of a clinical trial conducted by psychologists from the University of Basel and published in the journal Scientific Reports. After a severe traumatic brain injury, patients often exhibit problems in their social behavior.

Health - Pharmacology - 04.04.2019
New Project on Child Health in Tanzania
New Project on Child Health in Tanzania
Fondation Botnar has awarded CHF 7 million to researchers from Lausanne for further deployment of electronic diagnostic and treatment tools based on algorithms, which will help clinicians to manage febrile children.

Health - Pharmacology - 03.04.2019
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche's pending acquisition of Spark.

Pharmacology - Health - 02.04.2019
Novartis first-in-class Cosentyx approved in China for psoriasis patients
China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy   Cosentyx is the first b

Pharmacology - Health - 01.04.2019
Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
Data from Phase Ib study to be presented at American Association for Cancer Research (AACR) 2019 annual congress 73% overall response rate (ORR) irrespective of PD-L1 status or PI3KCA/AKT1/PTEN alter

Pharmacology - Health - 27.03.2019
Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary progressive MS with active disease
Mayzent (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years   Up to 80% of patients with relaps

Pharmacology - Health - 19.03.2019
FDA approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC

Business / Economics - Health - 18.03.2019

Pharmacology - Health - 15.03.2019
European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease

Health - Pharmacology - 14.03.2019
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019   C

Pharmacology - Health - 14.03.2019
European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously

Health - Life Sciences - 12.03.2019
EPFL software mines rich medical data while keeping it secure
MedCo , developed in the lab of EPFL professor Jean-Pierre Hubaux in collaboration with professor Bryan Ford 's DEDIS lab and the Lausanne University Hospital ( CHUV ), is the first operational system to protect sensitive patient data - including genetic information - so that it can be used collectively for crucial medical research.

Pharmacology - Health - 11.03.2019
FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announ

Health - Pharmacology - 11.03.2019
Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diag

Pharmacology - Health - 08.03.2019
European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N

Health - Pharmacology - 07.03.2019
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.

Pharmacology - Health - 07.03.2019
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
1 2 3 4 5 ... 34 Next »